Loading stock data…
LIVN
$61.00+0.90 (+1.50%)
Market ClosedLast close May 1
LivaNova PLC, a medical technology company, designs, develops, manufactures, markets, and sells products, therapies, and services in the United States, the United Kingdom, Germany, France, Italy, the Netherlands, Spain, Belgium, Poland, Sweden, Switzerland, Austria, Norway, Portugal, Finland, Denmark, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
LivaNova PLC in the Healthcare sector is trading at $61.00. The stock is currently 15% below its 52-week high of $71.92, remaining 4.1% above its 200-day moving average. Technical signals show neutral RSI of 38 and bearish MACD signal, explaining why LIVN maintains its current momentum and trend strength. The Whystock Score of 65/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 38) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$61.00
Potential Upside
5%
Whystock Fair Value$64.05
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus11 analysts
Mean target$79.18+29.8%
Range$67.00 – $90.00
Fundamentals
LivaNova PLC, a medical technology company, designs, develops, manufactures, markets, and sells products, therapies, and services in the United States, the United Kingdom, Germany, France, Italy, the Netherlands, Spain, Belgium, Poland, Sweden, Switz...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$3.56B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.97
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-17.61%
Volume
Today's trading volume
632,347
Recent News
AxoGen (AXGN) Surges 7.5%: Is This an Indication of Further Gains?
AxoGen (AXGN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Should FDA Approval of aura6000 Sleep Apnea Therapy Require Action From LivaNova (LIVN) Investors?
On March 19, 2026, LivaNova announced that the FDA granted premarket approval for its aura6000 System, a proximal hypoglossal nerve stimulation therapy for adults with moderate to severe obstructive sleep apnea who cannot use or benefit from first-line options like positive airway pressure. Backed by the rigorously designed OSPREY randomized controlled trial and plans for an MRI-compatible, rechargeable next-generation device, this approval positions LivaNova to expand its neuromodulation...
LivaNova (LIVN) Announces FDA Approval of aura6000 System for Obstructive Sleep Apnea
LivaNova PLC (NASDAQ:LIVN) is one of the 12 Best UK Stocks to Buy According to Hedge Funds. On March 19, 2026, LivaNova PLC (NASDAQ:LIVN) announced that the FDA granted premarket approval for its aura6000 System for treating adults with moderate to severe obstructive sleep apnea. The system uses proximal hypoglossal nerve stimulation to address patients […]
LivaNova Expands OSA Care With FDA-Approved aura6000 System
LIVN wins FDA nod for its aura6000 sleep apnea system, marking a pivotal step in neurostimulation with strong trial results and new growth potential.
Strength Seen in Tandem Diabetes Care (TNDM): Can Its 9.1% Jump Turn into More Strength?
Tandem Diabetes Care (TNDM) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.